Company profile
ABVC BioPharma, Inc.
NASDAQ: ABVC · Healthcare · Biotechnology
#971 of 1,418 Healthcare companies by revenue
EA Score
41DFH 35DQ 52GM 28SS 56
v0.1 · 65/100 weight · provisional
↑ disclosure history, listing tenure · ↓ Piotroski F, operating margin
Methodology →Revenue TTM
-$796.0k
Rev growth YoY (TTM)
-303.4%
Net income (FY)
-$7.9M
Employees
18
as of 2026-08-21
Market cap
$23.1M
as of 2026-08-21
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$296.0k$296.0k2025
Net income-$7.9M-$7.9M2025
Operating income-$7.2M-$7.2M2025
Total assets$21.1M$21.1M2025
Liabilities$7.8M$7.8M2025
Equity$11.1M$11.1M2025
Revenue trend
FY2019 – FY2025 · USD
FY19
FY19
FY20
FY21
FY22
FY23
FY25
FY25
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is ABVC BioPharma, Inc.’s revenue?
ABVC BioPharma, Inc. booked $296.0k in FY2025 revenue — among the slowest-growing Healthcare companies we track, at a -2671.8% net margin.
Peers · Healthcare
Cannabis Bioscience International Holdings, Inc.18DNexalin Technology, Inc.34DBioAtla, Inc.15DTempest Therapeutics, Inc.24DMotus GI Holdings, Inc.——CannAmerica Brands Corp.——Neighbors
Alameda →Key facts
CEOUttam Yashwant Patil
SectorHealthcare
IndustryBiotechnology
HeadquartersFremont, CA
ExchangeNASDAQ: ABVC
Employees18
IPO date2004-11-10
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.